Clinical Trial Update: An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML) [Phase 1]

View source ↗

Summary

This open-label, single-centre Phase 1 mass balance C-14 study in patients with acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Not disclosed

Snippet

Sponsor: AstraZeneca | Conditions: Acute Myeloid Leukaemia | Phase 1 | Status: COMPLETED